查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1916943

放射性核种药物偶联物市场按释放类型、标靶分子、适应症、通路和最终用户划分－2026-2032年全球预测

Radionuclide Drug Conjugate Market by Emission Type, Targeting Molecule, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年放射性核种药物复合物市值为 8.4027 亿美元，预计到 2026 年将成长至 9.0601 亿美元，年复合成长率为 10.77%，到 2032 年将达到 17.2027 亿美元。

关键市场统计数据
基准年 2025 8.4027亿美元
预计年份：2026年 9.0601亿美元
预测年份 2032 1,720,270,000 美元
复合年增长率 (%) 10.77%

本书权威地介绍了放射性核种药物偶联物，阐述了其科学原理、临床应用前景以及构成当前策略的操作前提。

放射性核种药物偶联物融合了标靶分子治疗和放射性有效载荷递送技术，旨在选择性地将细胞毒性辐射递送至恶性组织，同时保护健康组织。这些药物将标靶配体与放射性同位素结合，使临床医生能够利用分子辨识技术定位治疗性辐射，某些偶联物也具备诊断影像功能，可作为治疗性诊断策略的一部分。这种双重效用有助于优化患者选择和治疗监测，进一步激发了临床和商业性对这些治疗方法的兴趣。

技术突破、临床检验和不断发展的护理模式如何重塑放射性药物治疗的竞争格局和运作模式

放射性核种药物偶联物领域正经历着变革性的转变，这主要得益于技术创新、不断累积的临床证据以及不断发展的供应生态系统。同位素生产技术的进步，包括新型迴旋加速器和发生器平台，提高了供应的可靠性，并实现了更广泛的地理分布。同时，靶向分子设计的突破，涵盖单株抗体、胜肽和优化的小分子，拓展了可靶向的肿瘤类型，并改善了肿瘤与正常组织的比例。

对2025年关税调整对放射性药物相关人员的供应链经济、生产决策和策略采购的影响进行务实分析

美国在2025年生效的关税政策调整，对放射性核种药物偶联物的生产商、物流业者和临床医生而言，都构成重要的考量。进口关税和归类规则的调整将影响关键投入品的到岸成本，例如用于放射性标记和品管的同位素、前驱化学品和特殊耗材。同样重要的是，活性药物成分和医用级组件的关税待遇变化，其影响可能因供应链是垂直整合还是依赖跨境供应商而有所不同。

基于详细细分市场的洞察，揭示了通路、交付方式、终端用户环境、目标分子和适应症如何决定临床和商业策略。

细分市场分析揭示了不同分销管道、照射方式、最终用户、目标分子和适应症所带来的策略重点差异。不同管道的分销运作要求各不相同：医院药房环境需要与患者照护流程和辐射安全基础设施相整合；在线药房管道侧重于远程物流和门诊病人用药的规范化配送；而零售药房则侧重于门诊病人配药流程和社区层面的宣传活动。这些差异影响着商业性策略，并决定在培训、基础设施和伙伴关係方面的投资何时才能最为有效。

美洲、欧洲、中东和非洲以及亚太地区的区域基础设施、监管差异和投资模式如何导致准入和部署策略的差异化

区域趋势正在以不同的方式影响美洲、欧洲/中东/非洲和亚太地区开发商、製造商和供应商的战略重点。在美洲，先进的临床应用和高度集中的专业癌症治疗中心为早期采用新型放射性核素疗法创造了有利环境，而主要市场的监管和报销框架则强调临床疗效和成本效益的证据。这种区域背景支持对集中式生产和分销网络进行投资，以便服务于大都会圈的治疗中心，并支援协调一致的临床计画。

决定哪些组织能够在放射性药物生态系统中成功实现规模化发展的，是其竞争角色、伙伴关係和营运能力。

放射性核种药物偶联物领域由众多参与者主导，包括生物技术创新者、成熟的放射性药物公司、专业契约製造机构和学术转化研究中心。生物技术创新者透过新型靶点结构和First-in-Class的放射性组合来推动临床差异化，而成熟的製造商则提供更广泛的商业部署所需的规模、监管经验和分销网络。契约製造和服务供应商在实现快速生产、品管检测和放射性物质处理方面发挥关键作用，从而加快新兴开发商的临床应用进程。

采取切实可行的策略措施，协调科学重点、供应链韧性和相关人员参与，以加速放射性药物的负责任应用和商业性成功。

产业领导者应采取协作策略，整合科学差异化、切实可行的营运投资和相关人员参与。优先建构稳健的采购体系，为同位素和关键前驱物建立冗余供应链，并探索区域生产伙伴关係，以降低跨境政策和关税风险。同时，投资于能够预见放射性药物监管要求并随着临床需求成长而快速扩大生产规模的製造和品质系统。

我们采用透明的多学科研究途径，结合临床证据、技术检验、专家访谈和政策分析，以确保研究结果具有可操作性和可靠性。

本研究整合了同行评审的临床文献、监管指导文件、专利概况、公司资讯披露以及对临床医生、生产专业人员和供应链管理人员的专家访谈。证据基础着重于机制理解、临床试验结果、营运案例研究和政策分析，以全面展现整个生态系统。研究结果尽可能透过多资讯来源进行三角验证，以确保准确性并最大限度地减少偏差。

对技术进步、营运需求和伙伴关係重点的简要总结，突显了决定临床疗效能否转化为患者广泛应用的关键因素。

总之，放射性核种药物偶联物处于分子标靶治疗和放射治疗的策略性交会点，正从早期临床检验走向更广泛的临床应用。同位素生产技术、标靶配体设计和辅助成像技术的进步正在降低关键的技术壁垒，而不断涌现的临床证据正促使医疗机构重组治疗模式并增加对专业技术的投入。这些进展为能够将科学创新与实际应用相结合的相关人员创造了重要的机会。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 放射性核种药物复合物市场依释放类型划分

  • 阿尔法发射体
  • β射线放射体

9. 以标靶分子分類的放射性核种药物偶联物市场

  • 单株抗体
  • 胜肽
  • 低分子化合物

第十章 依适应症分類的放射性核种药物复合物市场

  • 神经内分泌肿瘤
  • 摄护腺癌

第十一章 放射性核种药物复合物市场（依分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 放射性核种药物复合物市场（依最终用户划分）

  • 医院
    • 大学医院
    • 社区医院
  • 研究所
  • 专科诊所

13. 各地区放射性核种药物复合物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 放射性核种药物复合物市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国放射性核种药物复合物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章美国放射性核种药物复合物市场

第十七章：中国放射性核种药物复合物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bayer AG
  • Curium Pharma SA
  • DongCheng Pharmaceutical Group
  • Eckert & Ziegler Strahlen-und Medizintechnik AG
  • Ion Beam Applications SA
  • Jubilant Pharmova Limited
  • Lantheus Holdings, Inc.
  • Nordion Inc.
  • Novartis AG
  • Point Biopharma Solutions, Inc.
  • Telix Pharmaceuticals Limited
Product Code: MRR-AE420CB1540D

The Radionuclide Drug Conjugate Market was valued at USD 840.27 million in 2025 and is projected to grow to USD 906.01 million in 2026, with a CAGR of 10.77%, reaching USD 1,720.27 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 840.27 million
Estimated Year [2026] USD 906.01 million
Forecast Year [2032] USD 1,720.27 million
CAGR (%) 10.77%

An authoritative primer describing the scientific basis, clinical promise, and operational prerequisites that define current radionuclide drug conjugate strategies

Radionuclide drug conjugates represent a convergence of targeted molecular therapy and radioactive payload delivery, designed to selectively deliver cytotoxic radiation to malignant tissues while sparing healthy structures. These agents pair a targeting ligand with a radioactive isotope, enabling clinicians to exploit molecular recognition to localize therapeutic radiation and, in some constructs, provide diagnostic imaging capability as part of a theranostic strategy. This dual utility enhances patient selection and treatment monitoring, which has elevated the clinical and commercial interest in these modalities.

The maturation of targeting molecules, improvements in isotope production, and refinements in linker chemistry have collectively reduced off-target toxicity and improved therapeutic indices. Parallel advances in imaging, dosimetry, and patient management protocols have strengthened clinical confidence, encouraging broader adoption within specialized oncology centers. Consequently, stakeholders across the value chain-including radiopharmaceutical developers, hospital systems, and specialty pharmacies-are re-evaluating infrastructure, logistics, and clinical pathways to integrate these agents responsibly.

As the technology moves from early clinical validation into more routine clinical practice, attention has shifted toward scalable manufacturing, safe distribution, and reproducible clinical workflows. At the same time, regulatory frameworks are evolving to address the unique safety and handling considerations for radiopharmaceuticals. Taken together, these dynamics create a strategic inflection point: organizations that align science, operations, and commercial execution now can capture early advantages in a field poised to influence several oncology treatment paradigms.

How technological breakthroughs, clinical validation, and evolving care models are reshaping the competitive and operational environment for radiopharmaceutical therapies

The landscape for radionuclide drug conjugates is undergoing transformative shifts driven by technological innovation, expanded clinical evidence, and evolving delivery ecosystems. Advances in isotope production technologies, including novel cyclotron and generator platforms, have improved supply reliability and enabled wider geographic distribution. At the same time, breakthroughs in targeting molecule design-spanning monoclonal antibodies, peptides, and optimized small molecules-have expanded the range of addressable tumor types and improved tumor-to-normal tissue ratios.

Clinically, increasing evidence for therapeutic benefit in indications such as prostate cancer and neuroendocrine tumors has moved radionuclide therapies beyond compassionate-use contexts into structured clinical pathways. This shift is encouraging multidisciplinary teams to create integrated care pathways that combine imaging specialists, nuclear medicine physicians, medical oncologists, and pharmacy operations. As a result, service models within hospitals and specialty clinics are adapting, with dedicated treatment suites, enhanced radiation-safety programs, and new pharmacist competencies.

Commercially, novel reimbursement discussions and value-based contracting experiments are reshaping how payers, providers, and manufacturers negotiate access. This development is accelerating partnerships across academia, biotech, and established radiopharmaceutical manufacturers to co-develop therapeutic and diagnostic pairings. Collectively, these technological, clinical, and commercial transitions are redefining competitive positioning and creating fresh opportunities for organizations that can execute across science, supply chain, and clinical implementation.

Practical analysis of how 2025 tariff adjustments will affect supply chain economics, manufacturing decisions, and strategic sourcing for radiopharmaceutical stakeholders

Tariff policy changes in the United States for 2025 introduce material considerations for manufacturers, logistics providers, and clinical implementers of radionuclide drug conjugates. Adjustments to import duties and classification rules influence the landed cost of key inputs such as isotopes, precursor chemicals, and specialized consumables used in radiolabeling and quality control. Equally important, changes to tariff treatment for active pharmaceutical ingredients and medical-grade components can create differential impacts depending on whether supply chains are vertically integrated or dependent on cross-border suppliers.

These tariff shifts increase the strategic importance of supply chain resilience and localization. Manufacturers and healthcare systems are responding by diversifying supplier portfolios, evaluating regional production options, and accelerating investment in domestic production capacity for critical isotopes and precursors. In practice, this means closer collaboration between radiopharmaceutical developers and regional cyclotron operators, as well as reconsideration of inventory strategies to balance cost, decay-related loss, and service reliability.

Moreover, tariff-driven cost pressures are likely to cascade into contract negotiations with payers and health systems, prompting a focus on demonstrable clinical value, optimized utilization, and efficiency in delivery models. For stakeholders, the policy environment underscores the need for proactive scenario planning, cross-functional alignment on sourcing decisions, and targeted capital allocation to mitigate tariff exposure while maintaining clinical continuity and patient access.

Detailed segmentation-driven insights that reveal how distribution channels, emission modalities, end-user settings, targeting scaffolds, and indications determine clinical and commercial strategy

Segmentation analysis reveals differentiated strategic priorities across distribution channels, emission types, end users, targeting molecules, and indications. Distribution by channel shows a divergence in operational requirements: hospital pharmacy settings require integration with inpatient care pathways and radiation-safety infrastructure, online pharmacy channels emphasize remote logistics and regulated shipping for outpatient dosing, while retail pharmacy involvement focuses on outpatient dispensing workflows and community-level education. These distinctions shape commercial approaches and influence where investment in training, infrastructure, and partnerships will be most effective.

Emission type drives product design and clinical application. Alpha-emitting constructs tend to offer high linear energy transfer with short tissue penetration, making them attractive for micrometastatic disease and targeted cell kill, whereas beta-emitting constructs provide longer-range radiation useful for bulky disease and cross-fire effects. Appreciating these differences informs clinical trial design, patient selection strategies, and the development of accompanying diagnostic tools to optimize therapeutic index.

End-user segmentation further refines go-to-market tactics. Hospitals, including academic centers and community hospitals, demand robust protocols for inpatient and outpatient administration and benefit from institutional research infrastructure. Research institutes prioritize investigational flexibility and translational science partnerships, while specialty clinics emphasize streamlined outpatient workflows and rapid patient throughput. Tailoring commercial interactions to these varied settings improves adoption and supports sustained clinical integration.

Targeting molecule selection-monoclonal antibody, peptide, or small molecule-affects pharmacokinetics, tumor penetration, and manufacturing complexity. Monoclonal antibodies often require sophisticated biomanufacturing and may deliver prolonged tumor exposure, peptides typically enable rapid tumor targeting with simpler chemistry, and small molecules can provide favorable tissue permeability with ease of synthesis. These molecular attributes intersect with indication-specific needs; for example, neuroendocrine tumor therapies frequently exploit peptide receptor targets, while prostate cancer strategies commonly use small molecules or antibody fragments tuned to prostate-specific antigens. Together, these segmentation insights guide prioritization of R&D, clinical development pathways, and commercial models.

How regional infrastructure, regulatory heterogeneity, and investment patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific drive differentiated access and deployment strategies

Regional dynamics are shaping strategic priorities for developers, manufacturers, and providers in distinct ways across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, advanced clinical adoption and concentration of specialized oncology centers create a favorable environment for early implementation of novel radionuclide therapies, while regulatory and reimbursement frameworks in key markets emphasize evidence of clinical benefit and cost-effectiveness. This regional context supports coordinated clinical programs and investment in centralized production and distribution networks that can serve large metropolitan treatment centers.

By contrast, Europe, Middle East & Africa exhibits heterogeneous capabilities, with advanced nuclear medicine expertise concentrated in select European countries and varied regulatory and infrastructure readiness across the broader region. This heterogeneity necessitates differentiated market-access strategies and localized partnerships that align production and clinical training with regional capacity. Increasing collaboration across academic consortia and pan-regional initiatives is accelerating knowledge transfer and creating shared pathways for patient access.

In the Asia-Pacific region, rapid capacity building, investments in cyclotron infrastructure, and rising oncology care demand are creating a dynamic environment for radiopharmaceutical deployment. Several countries are expanding clinical trial activity and investing in domestic manufacturing to reduce dependency on imports. Consequently, stakeholders are prioritizing regionally tailored commercial models, local regulatory engagement, and scalable delivery solutions to meet both urban and decentralized care needs. Across all regions, cross-border collaboration on supply chain logistics and harmonization of safety standards remains a priority to ensure consistent patient access.

A synthesis of competitive roles, partnerships, and operational capabilities that determine which organizations will scale successfully in the radiopharmaceutical ecosystem

Competitive dynamics in the radionuclide drug conjugate space are shaped by players spanning biotech innovators, established radiopharmaceutical firms, specialized contract manufacturing organizations, and academic translational centers. Biotech innovators are driving clinical differentiation through novel targeting constructs and first-in-class emission combinations, while established manufacturers contribute scale, regulatory experience, and distribution networks necessary for broader commercial rollout. Contract manufacturing and service providers play a critical role in enabling agile production, quality-control testing, and handling of radioactive materials, thereby reducing time-to-clinic for emerging developers.

Academic and research institutions continue to be essential sources of discovery and translational expertise, frequently collaborating with industry partners to de-risk early clinical stages. Strategic alliances, licensing deals, and joint development agreements are common mechanisms for accelerating access to isotopes, targeting ligands, and complementary diagnostic assets. Additionally, an emerging cohort of logistics and specialty pharmacy providers is building capabilities in cold-chain management, just-in-time delivery, and on-site radiolabeling support, which are essential to operationalize therapies with short isotope half-lives.

Overall, competitive advantage accrues to organizations that can integrate scientific differentiation with reliable manufacturing, regulatory clarity, and nimble distribution. Firms that invest in multi-stakeholder partnerships and demonstrate operational excellence in handling radiopharmaceutical-specific challenges will be best positioned to scale adoption across clinical settings.

Actionable strategic moves that align scientific priorities, supply resilience, and stakeholder engagement to accelerate responsible adoption and commercial success in radiopharmaceuticals

Industry leaders should pursue a coordinated strategy that aligns scientific differentiation with pragmatic operational investments and stakeholder engagement. Prioritize resilient sourcing by establishing redundant supply lines for isotopes and critical precursors, while exploring regional production partnerships to mitigate cross-border policy and tariff exposures. Simultaneously, invest in manufacturing and quality systems that anticipate regulatory expectations for radiopharmaceuticals and enable rapid scale-up when clinical demand intensifies.

Operationally, strengthen clinical adoption by supporting end-user readiness: develop training programs for hospital pharmacy teams and nuclear medicine staff, design standardized administration protocols for academic and community hospitals, and create streamlined workflows for specialty clinics and research institutes. On the commercial front, engage proactively with payers and health technology assessment bodies to articulate clinical value propositions, support real-world evidence generation, and pilot reimbursement models that reflect total-cost-of-care benefits. Forge alliances with logistics and specialty pharmacy partners to ensure dependable distribution and to address the unique cold-chain and radioactive handling requirements.

Finally, align R&D priorities with segmentation realities: match targeting modalities to indication-specific biology, optimize emission selection based on disease burden and microenvironment, and design companion diagnostics to improve patient selection. By adopting an integrated approach that combines supply chain resilience, clinical operations, and payer engagement, organizations can accelerate responsible adoption and create sustainable pathways for growth.

Transparent and multidisciplinary research approach combining clinical evidence, technical validation, expert interviews, and policy analysis to ensure practical and reliable insights

This research synthesis integrates peer-reviewed clinical literature, regulatory guidance documents, patent landscapes, company disclosures, and primary expert interviews with clinicians, manufacturing specialists, and supply-chain managers. The evidence base emphasizes mechanistic understanding, clinical trial outcomes, operational case studies, and policy analyses to capture a holistic view of the ecosystem. Wherever possible, findings were triangulated across multiple information sources to ensure accuracy and minimize bias.

Qualitative inputs included structured interviews with practicing nuclear medicine physicians, hospital pharmacists, and cancer center administrators to understand real-world workflows and adoption barriers. Technical validation drew on manufacturing experts and radiochemistry specialists to assess production feasibility, handling constraints, and quality-control challenges. Policy analysis referenced recent regulatory guidance and tariff notifications to interpret implications for cross-border supply and local production strategies.

Analytical methods combined thematic synthesis of qualitative insights with scenario-based impact analysis to explore how operational, regulatory, and commercial variables interact. The methodology prioritized transparent assumptions and documented evidence pathways so that conclusions remain actionable for decision-makers seeking to align research priorities, capital allocation, and commercialization plans.

Concise synthesis of technological progress, operational imperatives, and partnership priorities that will determine whether clinical promise translates into broad patient access

In summary, radionuclide drug conjugates occupy a strategic intersection of molecular targeting and radiotherapy that is progressing from early clinical validation toward broader clinical integration. Progress in isotope production, targeting-ligand engineering, and supportive imaging approaches has reduced key technical barriers, while evolving clinical evidence is prompting healthcare providers to reconfigure delivery models and invest in specialized capabilities. These developments create meaningful opportunities for stakeholders that can align scientific innovation with operational readiness.

However, successful scale-up depends on solving practical challenges: establishing resilient supply chains, navigating changing tariff and regulatory landscapes, and ensuring end-user preparedness across hospitals, specialty clinics, and research institutes. Strategic partnerships among developers, manufacturers, logistics providers, and clinical centers will be essential to bridge gaps in capacity and expertise. Ultimately, organizations that combine durable technical differentiation with disciplined execution in manufacturing, distribution, and payer engagement will be best positioned to translate scientific promise into sustained clinical impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Radionuclide Drug Conjugate Market, by Emission Type

  • 8.1. Alpha Emitter
  • 8.2. Beta Emitter

9. Radionuclide Drug Conjugate Market, by Targeting Molecule

  • 9.1. Monoclonal Antibody
  • 9.2. Peptide
  • 9.3. Small Molecule

10. Radionuclide Drug Conjugate Market, by Indication

  • 10.1. Neuroendocrine Tumor
  • 10.2. Prostate Cancer

11. Radionuclide Drug Conjugate Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Radionuclide Drug Conjugate Market, by End User

  • 12.1. Hospital
    • 12.1.1. Academic Hospital
    • 12.1.2. Community Hospital
  • 12.2. Research Institute
  • 12.3. Specialty Clinic

13. Radionuclide Drug Conjugate Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Radionuclide Drug Conjugate Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Radionuclide Drug Conjugate Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Radionuclide Drug Conjugate Market

17. China Radionuclide Drug Conjugate Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Bayer AG
  • 18.6. Curium Pharma S.A.
  • 18.7. DongCheng Pharmaceutical Group
  • 18.8. Eckert & Ziegler Strahlen- und Medizintechnik AG
  • 18.9. Ion Beam Applications S.A.
  • 18.10. Jubilant Pharmova Limited
  • 18.11. Lantheus Holdings, Inc.
  • 18.12. Nordion Inc.
  • 18.13. Novartis AG
  • 18.14. Point Biopharma Solutions, Inc.
  • 18.15. Telix Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ALPHA EMITTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ALPHA EMITTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ALPHA EMITTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY BETA EMITTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY BETA EMITTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY BETA EMITTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY NEUROENDOCRINE TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY NEUROENDOCRINE TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY NEUROENDOCRINE TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ACADEMIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ACADEMIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ACADEMIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COMMUNITY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COMMUNITY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COMMUNITY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 118. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 121. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 139. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 142. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 146. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 149. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)